Skip to main content
Clinical Trials/EUCTR2005-001055-38-IT
EUCTR2005-001055-38-IT
Active, not recruiting
Not Applicable

RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE, ALONE OR ASSOCIATED WITH HIGHDOSE CYTARABINE, FOLLOWED BY RESPONSE- AND AGE-TAILORED RADIOTHERAPY FOR IMMUNOCOMPETENT PATIENTS WITH NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP IELSG0 sites80 target enrollmentApril 4, 2007

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP IELSG
Enrollment
80
Status
Active, not recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 4, 2007
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP IELSG

Eligibility Criteria

Inclusion Criteria

  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE AND HIGH-DOSE CYTARABINE WITH OR WITHOUT THIOTEPA, AND WITH OR WITHOUT RITUXIMAB, FOLLOWED BY BRAIN IRRADIATION vs. HIGH-DOSE CHEMOTHERAPY SUPPORTED BY AUTOLOGOUS STEM CELLS TRANSPLANTATION FOR IMMUNOCOMPETENT PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA - IELSG
EUCTR2009-012432-32-DEniversity Medical Center Freiburg Dept. Klinikum Stuttgart, Stuttgart Cancer Center200
Completed
Phase 2
Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Transplantation For Immunocompetent Patients With Newly Diagnosed Primary CNS LymphomaCentral Nervous System Lymphoma
DRKS00003763niversitätsklinikum Freiburg, Abt. Med 1, Hämatologie/ Onkologie227
Active, not recruiting
Not Applicable
Randomized phase II trial on primary chemotherapy with high-dose methotrexate and high-dose cytarabine with or without thiotepa, and with or without rituximab, followed by brain irradiation vs. high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed primary cns lymphoma. - IELSG 32newly diagnosed primary CNS lymphoma in immunocompetent patientsMedDRA version: 9.1Level: LLTClassification code 10036685
EUCTR2009-012432-32-ITIELSG-International Extranodal Lymphoma Study Group126
Active, not recruiting
Not Applicable
Et randomiseret fase ll studie af primær kemoterapi med højdosis Methotrexat oghøjdosis Cytarabin med eller uden thiotepa og med eller uden Rituximab efterfulgtaf strålebehandling eller højdosis kemoterapi med autolog stamcelletransplantationhos immunkompetente patienter med nydiagnosticeret primært CNS-lymfom.ewly diagnosed Primary CNS LymphomaTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2009-012432-32-DKInternational Extranodal Lymphoma Srudy Group IELSG126
Active, not recruiting
Not Applicable
Randomised phase II trial on primary chemotherapy with high-dose Methotrexate and high-dose Cytarabine with or without Thiotepa, and with or without Rituximab, followed by brain irradiation vs high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed Primary CNS Lymphoma. - IELSG 32
EUCTR2009-012432-32-GBniversity Hospital Southampton NHS Foundation Trust126